Hypothesis

Age‑related erythropoietin (EPO) resistance is driven by marrow adipocyte‑derived leptin that suppresses HIF‑2α activity in osteolineage stromal cells, thereby diminishing local EPO production and inducing stromal SOCS3 expression that blunts EPOR‑JAK2‑STAT5 signaling in hematopoietic stem and progenitor cells (HSPCs).

Mechanistic Rationale

With aging, bone marrow adiposity rises substantially (1), and adipocytes secrete leptin in proportion to their lipid stores. Leptin signaling through the leptin receptor (ObR) activates JAK2‑STAT3 in stromal cells, which induces SOCS3, a potent inhibitor of JAK2 activity. SOCS3 can cross‑talk with the EPOR complex, attenuating EPO‑triggered JAK2‑STAT5 phosphorylation in nearby HSPCs. Simultaneously, leptin‑activated STAT3 represses HIF‑2α transcription in osteoblasts and perivascular stromal cells, lowering the hypoxic drive for EPO synthesis within the niche (2). The resulting dual hit—reduced autologous EPO and heightened intracellular antagonism—explains the inappropriately low serum EPO and blunted erythropoietic response observed in unexplained anemia of the elderly (3).

This mechanism integrates the metabolic state dependency of EPO noted in obesity versus leanness: in obesity, high leptin may paradoxically preserve cortical bone via alternate pathways, but in the aged marrow where adipocyte accumulation is accompanied by chronic inflammation, leptin’s inhibitory arm dominates (4).

Testable Predictions

1. Aged mice will show elevated marrow leptin protein and increased SOCS3 expression in CD45‑Ter119‑ stromal subsets compared with young controls.
2. Genetic deletion of ObR specifically in leptin receptor‑positive stromal cells (using Lepr‑Cre) will rescue HIF‑2α target gene expression (Epo, Vegfa) and normalize EPOR‑STAT5 signaling in HSPCs, leading to higher hemoglobin despite unchanged renal EPO.
3. Pharmacologic blockade of leptin signaling with a peptidic ObR antagonist will reduce stromal SOCS3, increase niche EPO mRNA, and improve erythroid colony‑forming unit (CFU‑E) numbers in ex vivo marrow cultures from old mice.
4. Administration of recombinant leptin to young mice will recapitulate the aged phenotype: lowered marrow Epo transcript, increased stromal SOCS3, and decreased erythroid response to exogenous EPO.

Experimental Approach

• Mouse models: Young (3 mo) and aged (24 mo) C57BL/6J; Lepr‑fl/fl crossed with Cxcl12‑CreER for inducible stromal ObR knockout; treat with tamoxifen at 20 mo.
• Readouts: Flow cytometry for Lin⁻Sca1⁺c‑Kit⁺ (LSK) cells and CFU‑E assays; qPCR for Epo, Vegfa, SocS3 in FACS‑sorted CD45‑Ter119⁻PDGFRα⁺ stromal cells; Western blot for p‑STAT5 and p‑STAT3 in HSPCs after ex vivo EPO stimulation.
• Interventions: Chronic subcutaneous infusion of leptin‑antagonist peptide (Allo‑LEPT) or vehicle; serum hemoglobin, reticulocyte count, and marrow histology (H&E, adipocyte staining with Oil Red O).
• Statistical plan: Power analysis targeting 20 % hemoglobin increase, n = 8 per group, two‑tailed t‑test, α = 0.05.

If stromal leptin signaling is indeed the bottleneck, reversing it should uncouple the age‑related decline in EPO responsiveness without altering renal EPO output, providing a falsifiable framework for targeting the marrow niche in geriatric anemia.